Our company, SafeBlood BioAnalytica, exclusive distributor of CERUS company, is happy to announce that the INTERCEPT Red Blood Cell System authorization study has entered in Phase III.
The INTERCEPT Blood System for Red Cells will revolutionize Blood Transfusion Safety, securing blood transfusions from emerging or re-emerging pathogens! The INTERCEPT Blood System for Red Cells will complement the INTERCEPT Inactivation products that are already used globally ensuring the transfusion of Plasma and Platelets.
More than 1.300.000 Blood units have been inactivated worldwide with INTERCEPT Plasma and Platelets in routinely, in more than 90 Blood Centres in 15 countries. Please contact us for any further detail.